MX9402922A - Composiciones farmaceuticamente aceptables mejoradas. - Google Patents

Composiciones farmaceuticamente aceptables mejoradas.

Info

Publication number
MX9402922A
MX9402922A MX9402922A MX9402922A MX9402922A MX 9402922 A MX9402922 A MX 9402922A MX 9402922 A MX9402922 A MX 9402922A MX 9402922 A MX9402922 A MX 9402922A MX 9402922 A MX9402922 A MX 9402922A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
improved compositions
degree
acceptable improved
grams
Prior art date
Application number
MX9402922A
Other languages
English (en)
Inventor
Bernard Charles Sherman
Original Assignee
Bernard Charles Sherman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bernard Charles Sherman filed Critical Bernard Charles Sherman
Publication of MX9402922A publication Critical patent/MX9402922A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones farmacéuticas que tienen propiedades físicas y absorcion mejoradas, en las que se disuelve una droga hidrofobica en un sistema solvente que comprende cuando menos un alcohol que tiene un punto de ebullicion superior a los 100 degree C y una solubilidad en agua inferior a 10 g por 100 g a 20 degree C y un surfactante.
MX9402922A 1993-04-28 1994-04-22 Composiciones farmaceuticamente aceptables mejoradas. MX9402922A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ247516A NZ247516A (en) 1993-04-28 1993-04-28 Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant

Publications (1)

Publication Number Publication Date
MX9402922A true MX9402922A (es) 1997-05-31

Family

ID=19924336

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9402922A MX9402922A (es) 1993-04-28 1994-04-22 Composiciones farmaceuticamente aceptables mejoradas.

Country Status (19)

Country Link
US (1) US5843891A (es)
EP (1) EP0696920B1 (es)
JP (1) JPH08509475A (es)
CN (1) CN1124457A (es)
AT (1) ATE173635T1 (es)
AU (1) AU677660B2 (es)
BR (1) BR9406513A (es)
CA (1) CA2160880A1 (es)
CZ (1) CZ276995A3 (es)
DE (1) DE69414840T2 (es)
FI (1) FI955091A (es)
HU (1) HUT73664A (es)
IL (1) IL109401A0 (es)
MX (1) MX9402922A (es)
NO (1) NO954329L (es)
NZ (1) NZ247516A (es)
PL (1) PL311294A1 (es)
WO (1) WO1994025068A1 (es)
ZA (1) ZA942803B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
PL193414B1 (pl) * 1997-03-12 2007-02-28 Abbott Lab Dwuskładnikowa kompozycja farmaceutyczna do podawania cyklosporyny
CA2285983A1 (en) 1997-04-29 1998-11-05 Bernard Charles Sherman Emulsion preconcentrate comprising a cyclosporin and acetylated monoglyceride
NZ314702A (en) * 1997-04-29 1998-07-28 Bernard Charles Sherman Pharmaceutical composition comprising a cyclosporin in a solvent system of acetylated monoglycerides and a surfactant and optionally a hydrophilic solvent
FR2764509A1 (fr) * 1997-06-11 1998-12-18 Debiopharm Sa Compositions pharmaceutiques contenant du dichlorhydrate de cinchonine
EP1039893B1 (en) 1997-12-10 2011-02-02 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US20030054036A1 (en) * 2001-03-13 2003-03-20 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
DE60220519T2 (de) * 2001-04-20 2007-09-27 The University Of British Columbia, Vancouver Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
BR0213661A (pt) * 2001-10-19 2004-10-26 Isotechnika Inc Pré-concentrado de microemulsão e método para seu preparo, formulação farmacêutica e método para seu preparo, método para produzir imuno, supressão, método para aumentar os efeitos imuno supressores de isatx247, uso de formulação farmacêutica
US20050129718A1 (en) * 2001-12-20 2005-06-16 Sherman Bernard C. Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7498309B2 (en) 2003-11-29 2009-03-03 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
US7151085B2 (en) * 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006082588A2 (en) * 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
CN101715340A (zh) 2007-04-23 2010-05-26 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
WO2009042114A2 (en) 2007-09-21 2009-04-02 The Johns Hopkins University Phenazine derivatives and uses thereof
CN101918019B (zh) 2007-10-08 2014-11-26 奥里尼亚制药有限公司 包含钙调神经磷酸酶抑制剂或mTOR抑制剂的眼科组合物
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US8906414B1 (en) 2009-04-27 2014-12-09 University Of South Florida Methods and compositions for improving bioavailability of epigallocatechin gallate (EGCG)
AU2010259184B2 (en) 2009-06-09 2015-08-13 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
PT2462246T (pt) 2009-09-28 2017-12-11 Intarcia Therapeutics Inc Estabelecimento rápido e/ou terminação de entrega de fármaco em estado estável substancial
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR101211902B1 (ko) 2012-04-30 2012-12-13 주식회사 휴온스 사이클로스포린 함유 무자극성 나노에멀젼 안약 조성물
CA2914472C (en) * 2012-08-24 2019-09-03 Ashim K. Mitra Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
ES2974821T3 (es) 2015-11-10 2024-07-01 Sun Pharmaceutical Ind Ltd Formulaciones tópicas y usos de las mismas
BR112018067946A8 (pt) 2016-02-29 2022-11-08 Sun Pharma Global Fze Formulações tópicas contendo ciclosporina e usos das mesmas
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
WO2018098501A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
WO2024111590A1 (ja) * 2022-11-22 2024-05-30 一丸ファルコス株式会社 Ｒａｓ阻害ペプチドを含む組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS498246B1 (es) * 1965-07-15 1974-02-25
JPS5919525B2 (ja) * 1976-09-03 1984-05-07 武田薬品工業株式会社 注射剤
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
JPS6226220A (ja) * 1985-07-29 1987-02-04 Hishiyama Seiyaku Kk ケトプロフエン注射液
JP2577049B2 (ja) * 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
CH679119A5 (es) * 1988-05-13 1991-12-31 Sandoz Ag
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
JPH0558906A (ja) * 1991-09-06 1993-03-09 Sankyo Co Ltd シクロスポリン点眼製剤

Also Published As

Publication number Publication date
FI955091A0 (fi) 1995-10-25
DE69414840D1 (de) 1999-01-07
NO954329D0 (no) 1995-10-27
CZ276995A3 (en) 1996-03-13
EP0696920A1 (en) 1996-02-21
HUT73664A (en) 1996-09-30
FI955091A (fi) 1995-12-14
IL109401A0 (en) 1994-11-28
BR9406513A (pt) 1996-01-09
AU677660B2 (en) 1997-05-01
ZA942803B (en) 1996-01-22
CA2160880A1 (en) 1994-11-10
PL311294A1 (en) 1996-02-05
EP0696920B1 (en) 1998-11-25
US5843891A (en) 1998-12-01
CN1124457A (zh) 1996-06-12
WO1994025068A1 (en) 1994-11-10
AU6673494A (en) 1994-11-21
HU9503075D0 (en) 1995-12-28
NZ247516A (en) 1995-02-24
NO954329L (no) 1995-12-21
DE69414840T2 (de) 1999-04-22
ATE173635T1 (de) 1998-12-15
JPH08509475A (ja) 1996-10-08

Similar Documents

Publication Publication Date Title
MX9402922A (es) Composiciones farmaceuticamente aceptables mejoradas.
CA2004598A1 (en) Medicinal aerosol formulations
CA2111002A1 (en) Non-Chlorofluorocarbon Aerosol Formulations
CA2112014A1 (en) Antiallergic composition for ophthalmic or nasal use
SE9503143D0 (sv) New preparation
CA2216623A1 (en) Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections
ITGE930016A0 (it) Sistema elettrochirurgico trequarti,cosidetto "trocar".
TW273550B (es)
WO1995001168A3 (de) Pharmazeutische zubereitungen, die einen wirkstoff mit modifizierten amidingruppen enthält
CA2042972A1 (en) Treatment of ocular hypertension with a synergistic combination for ocular administration
WO2000072820A3 (en) Injectable anesthetic formulation
IT1246445B (it) Composizioni farmaceutiche con migliorate proprieta' di dissoluzione.
WO1995023586A3 (de) Kosmetische und/oder pharmazeutische zubereitungen
EP0842663A4 (en) OPHTHALMIC PREPARATIONS
AU674379B2 (en) Antitussive
ITRM950180V0 (it) Allestimenti per lo svolgimento del gioco "wormhole action match".
CA2042936A1 (en) Treatment of ocular hypertension with a synergistic combination for ophthalmic use
CA2074503A1 (en) Pharmaceutical formulation containing penciclovir
CA2129676A1 (en) Dextromethorphan Antitussive Compositions
CA2065889A1 (en) Increasing the choroidal blood flow
CA2113080A1 (en) Topical composition containing penciclovir
IE890275L (en) Pharmaceutical composition for 4-aroylimidazol-2-ones
JPS57126422A (en) Stabilizing method of lysozyme pharmaceutical
EP0509098A4 (en) Ataractic
Pasloske Molecular studies of the NMePhe Pilin of Pseudomonas aeruginosa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal